Cleveland biotechnology company Athersys Inc. (NASDAQ: ATHX) is bolstering its leadership team as it prepares for the potential approval of its MultiStem stem-cell therapy and commercialization.
The company announced in a news release on Wednesday, Jan. 15, that veteran pharmaceutical industry executive Ivor Macleod will join Athersys as chief financial officer on Jan. 31 “to help plan and execute the financial strategy through potential product commercialization.” Laura Campbell, the company’s senior vice president of finance, will continue to serve as principal accounting officer.
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published January 15, 2020.